Last updated on February 2020

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers


Brief description of study

This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.

Clinical Study Identifier: NCT03454451

Find a site near you

Start Over

University of Miami

Miami, FL United States
  Connect »

Yale School of Medicine

New Haven, CT United States
  Connect »

Carolina BioOncology Institute

Huntsville, NC United States
  Connect »

City Of Hope

Duarte, CA United States
  Connect »

UCSF Medical Center

San Francisco, CA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

The University of Chicago

Chicago, IL United States
  Connect »

The John Hopkins University

Baltimore, MD United States
  Connect »

St. Vincent's Hospital

Darlinghurst, Australia
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Monash Health

Clayton, Australia
  Connect »

Oncology Hematology Care, Inc.

Cincinnati, OH United States
  Connect »

UPMC Hillman Cancer Center

Pittsburgh, PA United States
  Connect »